The BioBeat24 half-day event, held at the Sainsbury Wellcome Centre in central London in May 2024, was all about exploring emerging opportunities both from research and clinical perspectives as well as understanding the fundraising environment for entrepreneurs. The UK Dementia Research Institute and BioBeat were co-organisers.
Ahead of BioBeat24, Iraida Soria-Espinosa, Senior Innovation & Business Manager at UK DRI, and Miranda Weston-Smith, Founder of BioBeat, caught up with keynote speaker Zoe Kourtzi, Professor of Computational Cognitive Neuroscience at the University of Cambridge.
BioBeat24: Driving solutions in neurodgeneration with digital will take place at the Sainsbury Wellcome Centre, London in the afternoon of 16 May 2024.
Zoe, we are thrilled you are delivering the keynote,
» Read more about: A critical time for AI, dementia and better brain health »
The University of Cambridge has participated in venture capital to invest in technologies emanating in the University since the 1980s. This paper explores its roles and how investment has grown. The University’s role ranges through investing into a fund alongside others, leading or co-leading on a fund and serving as the bond linking alumni investors into a fund.
This is an original manuscript of an article published by Taylor & » Read more about: Cambridge UK and University Venture Capital »
BioBeat23 provided a platform for investors, entrepreneurs, and industry experts to delve into the evolving world of biotechnology. Against the backdrop of economic adversity, this gathering of minds shed light on the key mindsets and strategies required for success in the biotech industry. Organised by Miranda Weston-Smith, Founder of BioBeat, and Alisa Molotova, Investment Manager at Martlet Capital, the event provided valuable insights for biotech industry professionals.
Ahead of BioBeat23, Miranda Weston-Smith, BioBeat founder, talks to Alisa Molotova, Investment Manager at Martlet and co-organiser of BioBeat23, about her investment journey.
Miranda: It’s a total pleasure working with you on BioBeat23: Out of adversity comes opportunity on 18 May at the Cambridge Union. I’m curious to know, how did you get into biotech investing?
Alisa: I spent years in the lab studying the intricacies of cellular biology and regenerative medicine.
» Read more about: A newcomer’s view on heatlthcare investment »
Live-streamed to over 600 delegates from AstraZeneca’s new R&D Centre in Cambridge, UK, this year’s BioBeat Summit focused on optimising outcomes through digital innovation in clinical trials and beyond. BioBeat founder Miranda Weston-Smith opened the event with the message that we are at our most impactful when technology and humanity converge, bringing new opportunities for creating progress and value.
We need to share our experiences about what works, to build on the valuable insights we’ve all gained over the past two years.
» Read more about: Connecting humanity and technology to improve health »
This report highlights 30 trendsetters from across the UK who are tackling the biggest health challenges of our time. This year’s report also features insights from five alumni who share their vision for the opportunities that lie ahead as we move through the pandemic and beyond.
The BioBeat20 summit, hosted in partnership with the Francis Crick Institute, explored the opportunities for adopting and investing in data-driven health.
A global audience with more than 200 attendees from across the UK, USA, Brazil and Europe joined the virtual meeting on 17 November.
Download the report of the meeting.
» Read more about: Data-driven health for compassionate and ethical care »
The BioBeat20 Summit, hosted in partnership with the Francis Crick Institute, brought together the life sciences community to explore the opportunities for adopting and investing in data-driven health. A global audience with more than 200 attendees from across the UK, USA, Brazil and Europe joined the virtual meeting. The Movers and Shakers BioBusiness 2020 report features the pioneers who are bringing us better health.
Accelerating cell and gene therapy was the topic of the BioBeat19 summit. Hosted at GSK Stevenage, it scrutinised how joining up science and value in cell and gene therapy can deliver global health impact. The trailblazers in biotech are featured in 50 Movers and Shakers in BioBusiness 2019.
On 19 November, the UK BioBeat19 summit goes to Stevenage to discuss the potential of cell and gene therapy and how to accelerate these transformational medicines. The organisers from GSK and BioBeat spoke to two panellists who gave a sneak peek of their remarks and agree wholeheartedly that the discovery side and clinical side work best when they are teamed up.
Sophie Papa, an oncologist at Guy’s Cancer at Guy’s and St Thomas’ NHS Trust,
» Read more about: Next generation cell & gene therapies: fine tuning the promise »
From genetic and molecular information to routinely-collected NHS patient data or novel measurements from clinical trials, biomedical data is everywhere.
The BioBeat18 summit, held on 15 November at the Wellcome Genome Campus in Cambridge, brought together scientists, innovators, entrepreneurs and investors to discuss opportunities for bringing disruptive biodata ideas to life.
» Read more about: BioBeat18: Disrupting biodata healthcare »
Every day huge amounts of data are captured and with it our ability to harvest new biological insights to improve healthcare for everyone. The technological possibilities are vast. At the BioBeat18 summit: Disrupting biodata healthcare, leaders will explore how to build sustainable biodata healthcare businesses. The congress will take place on 15 November at the Wellcome Genome Campus.
Ahead of the forum, we (Jo Mills, Entrepreneurship and Innovation Manager at the Wellcome Genome Campus,
» Read more about: BioBeat18: Usability challenges of biodata in healthcare »
The BioBeat18 summit debated Disrupting biodata healthcare, hosted at the Wellcome Genome Campus. 50 Movers and Shakers in BioBusiness 2018 identifies 50 outstanding women who are revolutionising bioscience products for healthcare from the lab and the clinic to the boardroom, world of finance and ecosystem.
This Manifesto for biotech collaboration calls for strengthening the ties of biotech with academia and finance to build strong biotechs. Leaders set out key actions for success. The Manifesto arose from discussions at the BioBeat17 summit at the Francis Crick Institute.
Miranda has mentored and judged the IMAGINE IF! competition and accelerator programme in Cambridge for several years. We talk to her about being a mentor, the life sciences sector in Cambridge, and creating successful ventures.
Innovation Forum Cambridge (IFC): Why have you committed yourself as a mentor?
Miranda: The bio entrepreneurs the Innovation Forum attracts to IMAGINE IF! are impressive. They are bold, practical and ambitious to make the world a healthier place.
» Read more about: Innovation Forum Cambridge interviews IMAGINE IF! Mentor Miranda Weston-Smith »
As an advocate of innovation and collaboration in life science, BioBeat has recently released its 50 Movers and Shakers in BioBusiness 2017 report. This demonstrates the remarkable achievements of 50 women leaders and entrepreneurs across five key themes encompassing the entire bioscience translational spectrum. In four previous blogs, we explored the themes: Great Science, Financial Enablers, Collaboration, and Patient Impact.
In its ongoing support of this cause, BioBeat has recently released its 50 Movers and Shakers in BioBusiness 2017 report, recognising the remarkable impact that women leaders and entrepreneurs are making in life science across five key translational themes. In three previous blogs, we explored the report’s Great Science, Financial Enablers, and Collaboration themes. Below we look at the Patient Impact theme,
» Read more about: BioBeat’s Movers and Shakers 2017: Who’s helping to improve patient care? »
As an innovative collaborative platform for bioscience, BioBeat recently released its 50 Movers and Shakers in BioBusiness 2017 report. This demonstrates the exceptional leadership in life science across five key translational themes. In the last two blogs, we focused on the report’s Great Science and Financial Enablers themes, which recognized 10 talented scientists and 10 financial experts who are making a significant impact towards solving our global healthcare challenges.
As a collaborative platform for nurturing outstanding talent in UK bioscience, BioBeat publishes its annual Movers and Shakers in BioBusiness report to demonstrate the achievements of women leaders and entrepreneurs. This year the report recognises 50 of these talented women working across five key translational themes: Great Science, Financial Enablers, Collaboration, Patient Impact, and Infrastructure Innovation.
Below we focus on the report’s Financial Enablers theme, in which ten women leaders (including six Rising Stars) are recognised for driving exceptional investment and growth in the life sciences – and ultimately helping to make a difference to patients’ lives.
